About

Welcome to the Cardiometabolic Forum, an educational website developed under the auspices of the University of Glasgow and dedicated to the dissemination of the latest developments in the field of cardiometabolic diseases. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of cardiometabolic diseases, their treatments and clinical practice.

Our content is free from commercial bias and features leading experts sharing their knowledge and experience in the form of videos, podcasts, and slide deck publication summaries.

CMF membership is free for everyone. Register as a member and receive unlimited free access to all of the materials contained within the site.

FREEMEMBERSHIP

Publications

Free slide summaries for a selection of papers

The Steering Committee regularly select the most relevant and up-to-date publications for review, with slide summaries of the papers available to download.

Podcasts

Free podcasts hosted by our Steering Committee

Here you will find our Cardiometabolic Forum podcasts recorded by our Steering Committee

Latest Updates

Publications ▼
All
Publication thumbnail: Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled, Phase 2b, Clinical Trial

Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled, Phase 2b, Clinical Trial

Publication thumbnail: Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

Publication thumbnail: Glomerular and Tubular Effects of Dapagliflozin, Eplerenone and their Combination in Patients with Chronic Kidney Disease: A Post-hoc Analysis of the ROTATE-3 Study

Glomerular and Tubular Effects of Dapagliflozin, Eplerenone and their Combination in Patients with Chronic Kidney Disease: A Post-hoc Analysis of the ROTATE-3 Study

Publication thumbnail: Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Steering Committee